ライフサイエンスコーパス: IL-1 receptor

1 mphocytes) but not in mice deficient for the IL-1 receptor.

2 onal priming effect that was mediated by the IL-1 receptor.

3 a and IL-1beta, both of which signal through IL-1 receptor.

4 diates signaling downstream of the IL-18 and IL-1 receptors.

5 tivated TNF receptors but not with activated IL-1 receptors.

6 am of Toll-like receptors and interleukin-1 (IL-1) receptors.

7 to track and reciprocally delete or express IL-1 receptor 1 (IL-1R1) in specific cell types, includi

8 stinal lamina propria lymphocytes expressing IL-1 receptor 1 (IL-1R1) is the lymphoid tissue inducer

9 e central nervous system and are mediated by IL-1 receptor 1 (IL-1R1) on several distinct cell types.

10 Increased lethality depended on IL-1 receptor 1 (IL-1R1) signaling but not adaptive immu

11 Mice lacking IL-6 receptor (IL-6R) or IL-1 receptor 1 (IL-1R1) specifically on B cells have a

12 3 impairs cognition by activating microglial IL-1 receptor 1 (IL-1R1).

13 gene expression patterns, we identified the IL-1 receptor 1 (IL1R1) as a direct target of miR-BHRF1-

14 nstrate that a viral miRNA downregulates the IL-1 receptor 1 during EBV infection, which consequently

15 ter hypoxia/reoxygenation was accelerated in IL-1 receptor 1 knockout (IL-1R1 KO) mice, in mice recei

16 r necrosis, which increased its affinity for IL-1 receptor 1.

17 ue to their low expression of interleukin 1 (IL-1) receptor 1 and high expression of the decoy recept

18 tor antagonist (IL-1Ra) binds and blocks the IL-1 receptor-1 (IL-1R1), preventing signaling.

19 st cell types examined expressed a cytosolic IL-1 receptor 2 (IL-1R2) whose binding to pro-IL-1alpha

20 1 and high expression of the decoy receptor IL-1 receptor 2 and IL-1 receptor antagonist protein (IL

21 The type 1 IL-1 receptor (IL-1R1) and the IL-1 receptor accessory protein (IL-1RAcP) form a functi

22 in the interleukin 1 (IL-1) cytokine family, IL-1 receptor accessory protein (IL-1RAcP) is the co-rec

23 is: 2 IL33 SNPs (rs4742170 and rs7037276), 1 IL-1 receptor accessory protein (IL1RAP) SNP (rs10513854

24 sregulated expression of 11 genes, including IL-1 receptor accessory protein (IL1RAP), in all leukemi

25 increased expression of the IL-1 receptors, IL-1 receptor accessory protein and IL-1 receptor type 1

26 ch we measured binding to the IL-36 receptor/IL-1 receptor accessory protein complex and functional a

27 tor (IL-36R) and a shared subunit, IL-1RAcP (IL-1 receptor accessory protein).

28 plexed with the newly discovered alternative IL-1 receptor accessory protein, IL-1RAcPb.

29 the IL-33 receptor (ST2) and its coreceptor, IL-1 receptor accessory protein, into a single fusion pr

30 on of several markers such as interleukin-1 (IL-1) receptor accessory protein (IL1RAP), CD99, T-cell

31 more severe renal epithelial cell damage via IL-1 receptor activation in coculture compared with WT m

32 studied the role of the Toll/interleukin 1 (IL-1) receptor adapter and major inflammatory mediator m

33 A fibrotic infrapatellar fat pad express the IL-1 receptor and on exposure to IL-1alpha polarize to a

34 H2/TH17 cells expressed higher levels of the IL-1 receptor and phospho-p38 mitogen-activated protein

35 Carotid body glomus cells also expressed IL-1 receptor and responded to application of IL-1beta w

36 l for NF-kappaB activation via TNF receptor, IL-1 receptor and toll-like receptor 4.

37 tokine receptors, but rather, indirectly via IL-1 receptors and TNF receptors being expressed on glia

38 The effect of daily interleukin (IL)-1 receptor antagonist before stress on anhedonia was

39 IL-1beta following the severe stressor with IL-1 receptor antagonist (10 mug, intracerebroventricula

40 Mice given injections of an IL-1 receptor antagonist (anakinra) or antibodies to dep

41 IL-22 and IL-17 was not that of the classic IL-1 receptor antagonist (anakinra), because low concent

42 achieved a complete response to recombinant IL-1 receptor antagonist (anakinra).

43 y brain-specific overexpression of the human IL-1 receptor antagonist (hIL1ra(Ast)(+/+) mice) leads t

44 ammation: two specific receptor antagonists (IL-1 receptor antagonist (IL-1Ra) and IL-36 receptor ant

45 monocyte production of the natural inhibitor IL-1 receptor antagonist (IL-1Ra) and shifts production

46 IL-1beta, type I IL-1 receptor (IL-1R1), and IL-1 receptor antagonist (IL-1Ra) are all important regu

47 Cases had higher levels of IL-1 receptor antagonist (IL-1Ra) at all time points lea

48 Naturally-occurring IL-1 receptor antagonist (IL-1Ra) binds and blocks the I

49 Systemic blockade of IL-1 with IL-1 receptor antagonist (IL-1Ra) fully reversed infecti

50 The IL-1 receptor antagonist (IL-1Ra) has emerged as a pivot

51 AT1 downregulation, whereas incubation of an IL-1 receptor antagonist (IL-1ra) in EAE slices reduced

52 Treatment with recombinant IL-1 receptor antagonist (IL-1RA) inhibited IL-1 signali

53 Systemically administered IL-1 receptor antagonist (IL-1RA) was protective against

54 nction, whereas higher circulating levels of IL-1 receptor antagonist (IL-1RA), an endogenous inhibit

55 pha, of interleukin-1beta (IL-1beta), and of IL-1 receptor antagonist (IL-1ra), and correlated cytoki

56 IL-1alpha, IL-1beta, IL-18, IL-1 receptor antagonist (IL-1RA), and IL-8 levels were

57 knockout (IL-1R1 KO) mice, in mice receiving IL-1 receptor antagonist (IL-1RA), and in mice given the

58 Selected mice were treated with IL-1 receptor antagonist (IL-1RA), anti-IL-1beta, or rec

59 2) fragments of anti-CD3 mAb with or without IL-1 receptor antagonist (IL-1RA), or anti-IL-1beta mAb.

60 ecific B cells, plasmablasts, and IL-10- and IL-1 receptor antagonist (IL-1RA)-producing Breg cells w

61 of antiinflammatory molecules, specifically IL-1 receptor antagonist (IL-1Ra).

62 impairs production of the anti-inflammatory IL-1 receptor antagonist (IL-1Ra).

63 has co-evolved with a competitive inhibitor, IL-1 receptor antagonist (IL-1Ra).

64 induction of the anti-inflammatory cytokine IL-1 receptor antagonist (IL-1Ra, 16 +/- 1.7 ng/mL, mean

65 ut not prevented in IL-1RI(-/-) mice, nor by IL-1 receptor antagonist (IL-1RA; 10 mg/kg).

66 Mice were treated acutely with an IL-1 receptor antagonist (IL-1Ra; 100 mg/kg, s.c.) or ve

67 pression, which, in turn, down-regulated the IL-1 receptor antagonist (IL1Ra) expression.

68 evoked inflammatory stress to measure plasma IL-1 receptor antagonist (IL1RA) following low-dose Food

69 rs315952 in the IL1RN gene encoding IL-1 receptor antagonist (IL1RA) replicated its associat

70 We compared sequences of IL-1beta and IL-1 receptor antagonist (IL1RN), which is an IL-1beta h

71 0.01, r = -0.250, respectively), as well as IL-1 receptor antagonist (P < 0.01, r = -0.232 at the be

72 luble TNF receptor-1 (sTNFR1; p < .001), and IL-1 receptor antagonist (p value in mania < .001 and eu

73 ased plasma interleukin (IL)-6, IL-1beta and IL-1 receptor antagonist (R=-0.33 to -0.36, P<0.05).

74 Conversely, higher IL-1 receptor antagonist (ra) levels were found in healt

75 mation index ratio of interleukin (IL)-1beta/IL-1 receptor antagonist (ra) using enzyme-linked immuno

76 terleukin [IL]-1 beta [IL-1beta], rs1143623; IL-1 receptor antagonist [IL-1ra], rs4251961; IL-10, rs1

77 Blockade of IL-1beta with an IL-1 receptor antagonist abolished obesity-induced AHR a

78 breast cancer, we demonstrate here that the IL-1 receptor antagonist anakinra abrogates IL-22 produc

79 neutralization of IL-1 and IL-18, using the IL-1 receptor antagonist anakinra and anti-IL-18 antibod

80 ons in acute-phase hsCRP production with the IL-1 receptor antagonist anakinra and the IL-6 receptor

81 e activation to (1) assess the safety of the IL-1 receptor antagonist anakinra in conjunction with in

82 open-label, single-arm clinical trial of the IL-1 receptor antagonist anakinra in corticosteroid-resi

83 hibitory effect on IL-1beta secretion by the IL-1 receptor antagonist anakinra in phagocytes of patie

84 ne efficacy and safety of the association of IL-1 receptor antagonist anakinra plus methylprednisolon

85 Last, the IL-1 receptor antagonist anakinra protected animals agai

86 Similarly, intrathecal administration of the IL-1 receptor antagonist anakinra restored locomotor fun

87 Ex vivo, the addition of IL-1 receptor antagonist anakinra to whole blood reduced

88 Ex vivo, addition of the IL-1 receptor antagonist anakinra to whole blood reduced

89 Increased expression of IL-1 receptor antagonist and Glut4 in skeletal muscles a

90 Conversely, the anti-inflammatory IL-1 receptor antagonist and IL-4 were decreased in RA c

91 nd augmented production of anti-inflammatory IL-1 receptor antagonist and vascular endothelial growth

92 otoxin concentrations correlated with sputum IL-1 receptor antagonist concentrations (r = 0.510, P <

93 RNA against NLRP3, recombinant IL-1beta, and IL-1 receptor antagonist confirmed the role of NLRP3 inf

94 ized that a synonymous coding variant in the IL-1 receptor antagonist gene (IL1RN), rs315952, previou

95 Indeed, neutralization of IL-1 by IL-1 receptor antagonist has recently been shown to pote

96 ivated NLRC4 for sustained production of the IL-1 receptor antagonist IL-1Ra, which restrained NLRP3

97 sRNA-dependent production of IL-1, TSLP, and IL-1 receptor antagonist in NHBE cells was regulated by

98 Neonatal therapy using IL-1 receptor antagonist preserves choroid and prevents

99 Furthermore, daily injections of the IL-1 receptor antagonist prevented LCWE-mediated coronar

100 on of the decoy receptor IL-1 receptor 2 and IL-1 receptor antagonist protein (IL1Ra).

101 Anakinra, an IL-1 receptor antagonist protein, inhibited BAL TH2/TH17

102 Treatment with IL-1 receptor antagonist reduced hypoxia and slightly, b

103 binant human IL-1beta monoclonal antibody or IL-1 receptor antagonist resulted in a dose- and time-de

104 n IL-1beta neutralizing antibody or specific IL-1 receptor antagonist revealed the primary involvemen

105 ss, and intracerebroventricular injection of IL-1 receptor antagonist reverted both effects.

106 the human recombinant form of the endogenous IL-1 receptor antagonist used to treat rheumatoid arthri

107 A xanthine oxidase inhibitor or IL-1 receptor antagonist was administered during RSV inf

108 s etanercept (TNFalpha inhibitor), anakinra (IL-1 receptor antagonist), prednisone (NFkappaB transloc

109 se of anti-inflammatory mediators (IL-10 and IL-1 receptor antagonist).

110 periodic syndromes) and DIRA (deficiency of IL-1 receptor antagonist).

111 inhibitor, or blocking of IL-1 signaling by IL-1 receptor antagonist, abrogated the Th17-promoting e

112 With the exception of the IL-1 receptor antagonist, all IL-1 family cytokines lack

113 ID-19 patients early in the disease with the IL-1 receptor antagonist, anakinra.

114 ally benefiting from anakinra, a recombinant IL-1 receptor antagonist, but the utility of other biolo

115 ctively in SL rats and this was prevented by IL-1 receptor antagonist, consistent with a role for IL-

116 ow promising data with anakinra, recombinant IL-1 receptor antagonist, in patients with ST-segment-el

117 with the IL-1 blocker anakinra (recombinant IL-1 receptor antagonist, Kineret(R), Swedish Orphan Bio

118 Anakinra, IL-1 receptor antagonist, limited metastasis, and MDSC r

119 ved apocynin to inhibit NADPH oxidase (NOX), IL-1 receptor antagonist, or IL-18 binding protein to pr

120 nged with PMN-SA produced more IL-8 and less IL-1 receptor antagonist, TNF-alpha, activated caspase-1

121 expression of IL-1R-associated kinase M and IL-1 receptor antagonist, which are negative regulators

122 ing in life-long improved visual function in IL-1 receptor antagonist-treated OIR animals.

123 eta, IL-18, and IL-1alpha but low amounts of IL-1 receptor antagonist.

124 nd the anti-inflammatory cytokines IL-10 and IL-1 receptor antagonist.

125 he latter was abolished after treatment with IL-1 receptor antagonist.

126 al resolution was achieved with anakinra, an IL-1 receptor antagonist.

127 y lesions in this KD mouse model, blocked by IL-1 receptor antagonist.

128 ymphopoietin (TSLP) and was enhanced by anti-IL-1 receptor antagonist.

129 te more IL-1alpha and less IL-1RA, a natural IL-1 receptor antagonist.

130 tokines, such as interleukin (IL)-10 and the IL-1 receptor antagonist.

131 ocal treatment with anti-TNF-alpha antibody, IL-1-receptor antagonist, or indomethacin.

132 n postnatal development and investigated two IL-1 receptor antagonists, the competitive inhibitor ana

133 and can be suppressed by injections of anti-IL-1 receptor antibody.

134 IL-1 receptor appears to be a marker of neutrophilic inf

135 strated deficient TLR4-induced activation of IL-1 receptor-associated kinase (IRAK) 4, IRAK1, and TAN

136 f various innate immune receptors results in IL-1 receptor-associated kinase (IRAK)-1/IRAK-4-mediated

137 is and depends on the TLR-signaling molecule IL-1 receptor-associated kinase (IRAK-1) and its kinase

138 a greatly up-regulated the protein levels of IL-1 receptor-associated kinase (IRAK-1) and tumor-necro

139 guanine nucleotide exchange factor VAV-1 and IL-1 receptor-associated kinase 1 (IRAK-1), respectively

140 at Tbeta4 treatment suppressed expression of IL-1 receptor-associated kinase 1 (IRAK1) and tumor necr

141 S100A7, S100A8, and S100A9 (S100A7/8/9), and IL-1 receptor-associated kinase 1 (IRAK1) establish a re

142 ike receptor (TLR4) signaling first mediates IL-1 receptor-associated kinase 1 (IRAK1) nuclear transl

143 roduction via binding to and phosphorylating IL-1 receptor-associated kinase 1 (IRAK1), leading to IR

144 R-146a diminished or enhanced, respectively, IL-1 receptor-associated kinase 1 expression and induced

145 actor 7 gene expression and rapidly degraded IL-1 receptor-associated kinase 1 expression in plasmacy

146 adaptor protein (TIRAP), and the downstream IL-1 receptor-associated kinase 1, IL-1 receptor-associa

147 ession of IL-25 and IL-33 by upregulation of IL-1 receptor-associated kinase 1, transforming growth f

148 recruitment domain-containing protein 10 and IL-1 receptor-associated kinase 1.

149 t domain adaptor inducing IFN-beta (CARDIF), IL-1 receptor-associated kinase 4 (IRAK4), IkappaB kinas

150 he TLR-signaling pathways (MyD88, TIRAP/MAL, IL-1 receptor-associated kinase 4 [IRAK-4], TLR3, UNC-93

151 ownstream IL-1 receptor-associated kinase 1, IL-1 receptor-associated kinase 4, and TNF receptor-asso

152 IL-1 receptor-associated kinase M (IRAK-M) negatively re

153 nhibitor of NF-kappaB activation 3 (ABIN-3), IL-1 receptor-associated kinase M (IRAK-M), suppressor o

154 characterize an X chromosome-linked IRAK-1 (IL-1 receptor-associated kinase) polymorphism as an alte

155 IL-1 receptor-associated kinase-M (IRAK-M) is a macropha

156 mune components such as Toll-like receptors, IL-1 receptor-associated kinase/tumor necrosis factor re

157 The IL-1 receptor-associated kinases (IRAKs) are key regulat

158 Expression and/or activation of IL-1 receptor-associated protein kinase (IRAK), TNF rece

159 lyubiquitination of Pelle, an interleukin-1 (IL-1) receptor-associated kinase homolog in the Drosophi

160 Interleukin 1 (IL-1) receptor-associated kinases (IRAKs) are serine/thr

161 Further, we show that lack of interleukin-1 (IL-1) receptor attenuates gammaherpesvirus-driven B cell

162 IL-1 receptor blockade may provide a promising strategy

163 This unique approach limits IL-1 receptor blockade to sites of inflammation, while s

164 ing CGD patients who had severe colitis with IL-1 receptor blockade using anakinra.

165 al conditions in CGD that can be restored by IL-1 receptor blockade.

166 , comparable in extent to that obtained upon IL-1 receptor blockade.

167 Therapeutic IL-1-receptor blockade or NLRP3-inhibition reduces myelo

168 Rilonacept, a soluble IL-1 receptor chimeric fusion protein neutralizing IL-1a

169 cessory protein (IL-1RAcP) form a functional IL-1 receptor complex that is thought to mediate most, i

170 l cells, express a functional interleukin-1 (IL-1) receptor complex and respond with NF-kappaB activa

171 a coli strains, such as CFT073, express Toll/IL-1 receptor-containing (TIR-containing) protein C (Tcp

172 Additionally, IL-1 receptor-deficient mice show an increase in RABV pa

173 Both caspase-1-deficient and IL-1 receptor-deficient mice were protected from LCWE-in

174 h subsequent immunoglobulin E responses, and IL-1-receptor-deficient mice failed to induce iBALT form

175 (Ptpn6(DeltaPMN)) is sufficient to initiate IL-1 receptor-dependent cutaneous inflammatory disease,

176 erimental autoimmune encephalomyelitis in an IL-1 receptor-dependent manner.

177 or necrosis factor (TNF)- and interleukin-1 (IL-1) receptor-dependent activation of stellate cells an

178 ons to prevent autoimmune and interleukin-1 (IL-1) receptor-dependent, caspase-1-independent inflamma

179 and the adapter proteins each contain a Toll/Il-1 receptor domain (TIR domain).

180 The R753Q polymorphism in the Toll-IL-1 receptor domain of Toll-like receptor 2 (TLR2) has

181 esponse protein 88, and adaptor protein Toll/IL-1 receptor domain-containing adapter-inducing IFN-bet

182 TLR4 and TLR3 can both use the Toll-IL-1 receptor domain-containing adaptor inducing IFN-bet

183 hanisms dependent on and independent of Toll/IL-1 receptor domain-containing adaptor inducing IFN-bet

184 driven cytokine production we observed, Toll-IL-1 receptor domain-containing adaptor protein degradat

185 models BTK regulates the degradation of Toll-IL-1 receptor domain-containing adaptor protein, termina

186 d differentiation response gene 88, and Toll-IL-1 receptor domain-containing adaptor-inducing interfe

187 erferon-independent mechanism involving Toll-IL-1-receptor domain-containing adapter-inducing IFN-alp

188 TLR4-mediated nuclear factor-kappaB and Toll/IL-1 receptor-domain-containing adapter-inducing interfe

189 TIR (Toll/IL-1 receptor) domains mediate interactions between TLR

190 ammation after DSS colitis recovery, induced IL-1 receptor expression in subepithelial fibroblasts, a

191 toll-like receptors (TLRs) and interleukin (IL)-1 receptor family member signaling in postnatal gene

192 the IL-36 receptor (IL-36R), a member of the IL-1 receptor family, has been associated with various i

193 extracellular domains of each member of the IL-1 receptor family, including the IL-36 receptor (also

194 orphan members of the IL-1 ligand family and IL-1 receptor family, respectively.

195 oll-like receptors (TLRs) and interleukin-1 (IL-1) receptor family members.

196 Mice with global IL-1 receptor gene knockout or central IL-6 receptor kno

197 Expression of interleukin 23 (IL-23), IL-1 receptor I (IL-1RI), IL-17R, tissue inhibitors of m

198 hat MyD88, a known critical component of the IL-1 receptor I signaling pathway, plays a crucial role

199 deficient of IL-1beta (IL-1beta knockout) or IL-1 receptor (IL-1R knockout; n=10 each).

200 his study, we observed that mice lacking the IL-1 receptor (IL-1R) (IL1r(-/-)) or deficient in IL1-be

201 found that Trim24(-/-) T cells have reduced IL-1 receptor (IL-1R) expression, are refractory to IL-1

202 severe asthma compared with MMAs, including IL-1 receptor (IL-1R) family and nucleotide-binding olig

203 Members of the IL-1 Receptor (IL-1R) family include six receptor chains

204 Interleukin-1 (IL-1) and the IL-1 receptor (IL-1R) family play an important role in t

205 ablation or selective expression of IL-1 and IL-1 receptor (IL-1R) in either microglia or endothelia

206 targets, including cytokine signaling by the IL-1 receptor (IL-1R) pathway and inflammasome activatio

207 IL-12, and this bystander response required IL-1 receptor (IL-1R) signaling during early pulmonary i

208 e demonstrate a key role for T cell-specific IL-1 receptor (IL-1R) signals in the accumulation and su

209 Both IL-1alpha and IL-1beta ligate the same IL-1 receptor (IL-1R) that is present on nearly all cell

210 beta initiates cell signaling by binding the IL-1 receptor (IL-1R) whereas IL-1Ra acts as an antagoni

211 Transcriptome profiling of IL-1 receptor (IL-1R)-depleted senescent cells indicates

212 neas, but labeling was reduced and patchy on IL-1 receptor (IL-1R)-knockout mouse corneas (P < 0.05,

213 Thus, our observation that IL-1 receptor (IL-1R)-mediated signals were still requir

214 cal effects of IL-1beta are mediated through IL-1 receptor (IL-1R).

215 involving the Toll-like receptors (TLRs) and IL-1 receptor (IL-1R).

216 The type 1 IL-1 receptor (IL-1R1) and the IL-1 receptor accessory p

217 Genetic deletion of the IL-1 receptor (IL-1R1) in epithelial cells alleviated tu

218 We found that the type 1 IL-1 receptor (IL-1R1) is highly expressed in the mouse

219 IL-1beta, type I IL-1 receptor (IL-1R1), and IL-1 receptor antagonist (IL

220 thological effects in the CNS through type I IL-1 receptor (IL-1R1).

221 specifically binds to TNF and to the type I IL-1 receptor (IL-1RI).

222 LSC demonstrated increased expression of the IL-1 receptors, IL-1 receptor accessory protein and IL-1

223 1 (MAV-1) infection, using mice lacking the IL-1 receptor (Il1r1(-/-) mice).

224 eceptor, SIGIRR, or TIR8) is a member of the IL-1 receptor (ILR) family with distinct structural and

225 ade of IL-1beta or genetic deficiency of the IL-1 receptor in dendritic cells (DCs) and T cells impro

226 he development of POI required activation of IL-1 receptor in nonhematopoietic cells.

227 letion in hippocampal neurons confirmed that IL-1 receptor in the hippocampus was critical for stress

228 dney from fibrosis by limiting activation of IL-1 receptors in the kidney.

229 Loss of alpha-toxin or the IL-1 receptor increases Treg enrichment, whereas topical

230 We conclude that early blockade of the IL-1 receptor is therapeutic in acute hyperinflammatory

231 a neutralizing antibody and macrophages from IL-1 receptor knockout mice blocked the conditioned medi

232 clearance, deficiency in the interleukin 1 (IL-1) receptor led to a significant impairment.

233 eta (IL-1beta), an inflammatory cytokine and IL-1 receptor ligand, has diverse activities in the brai

234 Here we chimerized two IL-1 receptor ligands, IL-1beta and IL-1Ra, to create an

235 e reflected in nasal epithelium and included IL-1 receptor like 1, prostaglandin-endoperoxide synthas

236 ), which is the soluble form of interleukin (IL)-1 receptor-like 1, identifies risk in acutely decomp

237 ated with an IL-13-induced TH2 signature and IL-1 receptor-like 1 (IL1RL1) mRNA expression.

238 Two of these genes, IL33 and IL-1 receptor-like 1 (IL1RL1), act in one signal transdu

239 wide association studies identified IL33 and IL-1 receptor-like 1 (IL1RL1)/IL18R1 as asthma susceptib

240 riptional analyses identified lower level of IL-1 receptor-like 1 (ST2) expression in microglia/macro

241 ) and confirmed 4 asthma risk regions: 2q12 (IL-1 receptor-like 1 [IL1RL1]), 6p21 (HLA-DQA1), 9p24 (I

242 like 3 and gasdermin B (ORMDL3-GSDMB), IL33, IL-1 receptor-like 1 and IL-18 receptor 1 (IL1RL1-IL18R1

243 of the IL-33 receptor gene Il1rl1 (encoding IL-1 receptor-like 1, also known as ST2) in ILC2p and co

244 exhibited increased release of IL-1alpha and IL-1 receptor -mediated G-CSF production.

245 -specific Th1/Th17 immune responses required IL-1 receptor-mediated signals independent of IL-18 and

246 Pharmacologic disruption of CNS IL-1 receptor or IL-6 biological activity attenuated ano

247 at is prevented by genetic deletion of IL-1 (IL-1) receptor or apoptosis-associated speck-like protei

248 In inflammation-induced skin cancers, IL-1 receptor- or caspase-1-deficient mice, or mice spec

249 .001), toll-like receptors (TLR; p < 0.001), IL-1 receptor (p = 0.001), myeloid differentiation prima

250 Further studies revealed that IL-1 receptor (R)1 signaling was required for IL-17A-dep

251 r type 1 (IL-1RI) co-receptor, Toll-like and IL-1 receptor regulator (TILRR), amplifies IL-1 activati

252 including the IL-36 receptor (also known as "IL-1 receptor-related protein 2") and observed that IL-3

253 tiated by dimerization of intracellular Toll/IL-1 receptor resistance (TIR) domains.

254 mulation of IL-1alpha or IL-1beta binding to IL-1 receptor showed distinct interaction sites that cor

255 These in vitro effects require endothelial IL-1 receptors, shown by immunofluorescence to be expres

256 Silencing of the IL-1 receptor signaling in the central nervous system by

257 ction of hemolysin, which required NLRP3 and IL-1 receptor signaling in vivo.

258 sed in the Tg(CJD) hippocampus, and blocking IL-1 receptor signaling restored normal synaptic respons

259 ic inhibitor of Toll-like receptor (TLR) and IL-1 receptor signaling that prevents polarization towar

260 IL-1 receptor signaling via the transcription factors Ah

261 activation of a MyD88-dependent pathway and IL-1 receptor signaling, control of viral replication by

262 ion that increases EC immunogenicity through IL-1 receptor signaling.

263 eceptor-deficient macrophages is mediated by IL-1 receptor stimulation in the kidney.

264 rk1/2 following stimulation of the Toll-like/IL-1 receptor superfamily.

265 inhibitors of the NLRP3 inflammasome or the IL-1 receptor-targeting biological agent anakinra.

266 eutralizing antibody, recombinant IL-1RA, or IL-1 receptor-targeting small interfering RNA suppresses

267 which presumably distinguishes them from the IL-1 receptors that exhibit a more promiscuous ligand re

268 hermore, we show that the intracellular Toll/IL-1 receptor (TIR) domain of Nv-TLR can interact with t

269 inal death domain (DD) and a C-terminal Toll/IL-1 receptor (TIR) domain, separated by a short region.

270 r achieving LPS-inducible signaling via Toll/IL-1 receptor (TIR) domain-containing adapter-inducing i

271 Toll like receptors (TLRs) use Toll-IL-1 receptor (TIR) domain-containing adapters, such as

272 ibits TLR4 signaling and interacts with Toll-IL-1 receptor (TIR) domain-containing proteins of the re

273 distinct parts of the IL-1RI regulatory Toll IL-1 receptor (TIR) domain.

274 The Toll/IL-1 receptor (TIR) domains are crucial innate immune si

275 The Toll/IL-1 receptor (TIR) domains are crucial signaling module

276 signaling requires interactions of the Toll/IL-1 receptor (TIR) domains of the receptor and adapter

277 elino-3 in signaling pathways emanating from IL-1 receptors, Toll-like receptors, NOD-like receptors,

278 transcriptionally upregulated by ligands of IL-1 receptor/Toll-like receptor family members via the

279 phabeta knockout (KO) mice and perioperative IL-1 receptor type 1 (IL-1R1) blockade with the drug ana

280 We report that mature IL-1 signaling at IL-1 receptor type 1 (IL-1R1) is maintained at pH 6.2, b

281 Both Toll-like receptor 2 (TLR2) and IL-1 receptor type 1 (IL-1r1) upstream of MyD88 have bee

282 ceptors, IL-1 receptor accessory protein and IL-1 receptor type 1 (IL-1R1), and enhanced sensitivity

283 ion, pertussis toxin administration leads to IL-1 receptor type 1 (IL-1R1)-dependent IL-1beta express

284 e signaling and independent of IL-1alpha and IL-1 receptor type 1 (IL-1R1); nevertheless, IL-1alpha c

285 Our earlier work demonstrates that the IL-1 receptor type 1 (IL-1RI) co-receptor, Toll-like and

286 re mediated in part through IL-1, because an IL-1 receptor type 1 antagonist ameliorated the effects

287 Studies in IL-1 receptor type 1 knockout mice indicated that the in

288 r antagonist (IL-1Ra) and the decoy receptor IL-1 receptor type 2 (IL-1R2).

289 lance between IL-1 and its natural inhibitor IL-1 receptor type 2 (IL1R2) in women with endometriosis

290 atherosclerotic plaques in mice lacking both IL-1 receptor type I and apolipoprotein E (Il1r1(-)/(-)A

291 n, which in turn down-regulated sequentially IL-1 receptor type I and Sema3A expression through Erk/J

292 onal Par2 expression to repress sequentially IL-1 receptor type I and Sema3A expression.

293 kine signaling, including the IL-6 receptor, IL-1 receptor type I, and IL-1 receptor type II.

294 thology was reduced in mice deficient in the IL-1 receptor Type I, but the IL-1R-/- mice were fully p

295 the IL-6 receptor, IL-1 receptor type I, and IL-1 receptor type II.

296 ehavior associated with RSD did not occur in IL-1 receptor type-1 knock-out (IL-1R1(KO)) mice.

297 An absence of IL-17A or the IL-1 receptor was associated with reduced neutrophil rec

298 A robust increase in IL-1beta and IL-1 receptor were detected after TBI.

299 BALB/c mice deficient in NLRC4 or the IL-1 receptor were highly susceptible to orogastric but

300 3s, acetate-FFAR2 augments expression of the IL-1 receptor, which boosts IL-22 secretion in response